EUCTR2010-022102-41-SK进行中（未招募）1 期
A randomised, open label, multi-centre, Phase III study to investigate theefficacy of bendamustine compared to treatment of physician's choice inthe treatment of subjects with indolent Non-Hodgkin's Lymphoma (NHL)refractory to rituximab.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Indolent B-cell lymphoma: Grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage II (i.e. as any single mass > 5 cm in any direction) defined according to WHO Classification, 2008 (see Appendix 12.1. for WHO Classification and Appendix 12.2. for staging)
- •2. CT imaging in the Screening Phase (based on local evaluation) showing 2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or 1 clearly demarcated
- •lesion with a largest diameter = 2.0 cm. CT imaging performed at screening will be considered the baseline image.
- •3. Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimen:
- •Maintaining stable disease or failure to achieve PR to rituximab-based therapy (CT
- •imaging will support this finding, and will be performed at least 30 days after the last
- •dose of rituximab-based therapy)
- •Disease progression while on rituximab-based therapy (e.g. includes 4 weekly
- •courses of rituximab given at 6 week intervals)
- •Disease progression in subjects with stable disease or better response to rituximab based
- •therapy <6 months of the last dose of rituximab
- •Note: Subjects must have received at least 4 infusions of rituximab (either as
- •monotherapy or in combination with any chemotherapy).
- •4. Screening laboratory values:
- •Platelets = 75,000/µL (75 x 10 9 cells/L)
- •Absolute neutrophil count (ANC) = 1,000/µL (1.0 x 10 9 cells/L)
- •ALT, AST and alkaline phosphatase = 2.5 x ULN, and total bilirubin = 1.5 x ULN
- •(isolated predominantly indirect hyperbilirubinaemia due to Gilbert's syndrome is
- •acceptable for inclusion)
- •5. ECOG Performance Status of 0, 1, or 2
- •6. Age = 18 years
- •7. Estimated life expectancy of at least 3 months
- •8. Signed written informed consent obtained prior to performing any study-specific
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma as verified by biopsy confirmation (e.g. constitutional symptoms, poor performance status, fast growing tumour or increasing lactate dehydrogenase [LDH] levels)
- •2. Previous allogeneic stem cell transplant
- •3. Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla or to more than 3 vertebral bodies.
- •4. More than 10 mg prednisone daily at the time of randomisation
- •5. Prior bendamustine treatment within 1 year of randomisation not resulting in a CR or PR for at least 6 months
- •6. Known CNS involvement of indolent lymphoma
- •7. Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible.
- •8. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
- •9. Clinically significant cardiac disease including unstable angina, acute myocardial
- •infarction within 6 months from screening, congestive heart failure, and arrhythmia
- •requiring therapy, with the exception of extrasystoles or minor conduction abnormalities. Subjects with well controlled congestive heart failure and atrial arrhythmias need not be excluded but should be discussed with the study Medical Monitor.
- •10. Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
- •11. History of significant cerebrovascular disease or event with significant symptoms or sequelae
- •12. Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease per Investigator assessment)
- •13. Jaundice
- •14. Known HIV, Hepatitis B, or Hepatitis C positive
- •15. Creatinine clearance = 10 mL/min (measured or estimated using Cockcroft and Gault equation [Cockcroft, 1976])
- •16. Treatment with any known non-marketed drug substance or experimental therapy within 5-terminal half-lives or 4 weeks prior to screening, whichever is longer, or currently participating in any other interventional clinical study unless the sole purpose of the study is for collection of survival data
- •17. Known or suspected inability to comply with the study protocol
- •18. Lactating women, women with a positive pregnancy test at screening or women (of childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception from study start through last treatment dose and for 6 months following cessation of treatment. Female contraception must be individually recommended by an expert. Adequate contraception is defined as abstinence, oral contraceptive, either combined or progestogen alone, injectable progestogen, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device (IUD) or intrauterine system (IUS), male partner sterilisation (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for t
研究者
相似试验
进行中（未招募）
不适用
A randomised, open label, multi-centre, Phase III study to investigate the efficacy of bendamustine compared to treatment of physician`s choice in the treatment of subjects with indolent Non-Hodgkin Lymphoma (NHL) refractory to rituximab. - NDindolent B-cell Non-Hodgkin`s Lymphoma (NHL) that is refractory to rituximabMedDRA version: 9.1Level: LLTClassification code 10029601EUCTR2010-022102-41-ITMUNDIPHARMA RESEARCH LIMITED125
进行中（未招募）
1 期
A randomised, open label, multi-centre, Phase III study to investigate the efficacy of bendamustine compared to treatment of physician's choice in the treatment of subjects with indolent Non-Hodgkin's Lymphoma (NHL) refractory to rituximab.indolent B-cell Non-Hodgkin's Lymphoma (NHL) that is refractory to rituximabMedDRA version: 20.0 Level: PT Classification code 10029601 Term: Non-Hodgkin's lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022102-41-PTMundipharma Research Ltd.109
进行中（未招募）
1 期
A randomised study to investigate the efficacy of bendamustine in subjects with indolent Non-Hodgkin's Lymphoma (NHL) refractory to rituximab.indolent B-cell Non-Hodgkin's Lymphoma (NHL) that is refractory to rituximabMedDRA version: 18.1Level: PTClassification code 10029601Term: Non-Hodgkin's lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022102-41-PLMundipharma Research Ltd.125
进行中（未招募）
1 期
Study to compare 2 chemotherapy, one with Irinotecan liposome injection in addition to combination of chemotherapy and one with standard chemotherapy in patients with pancreatic cancerPreviously Untreated, Metastatic Pancreatic AdenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-003585-14-FRIpsen Bioscience, Inc.750
进行中（未招募）
1 期
Study to compare 2 chemotherapy, one with Irinotecan liposome injection in addition to combination of chemotherapy and one with standard chemotherapy in patients with pancreatic cancerPreviously Untreated, Metastatic Pancreatic AdenocarcinomaMedDRA version: 27.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003585-14-ATIpsen Bioscience, Inc.770